Spots Global Cancer Trial Database for Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer

Official Title: Repurposing Drugs as Immunotherapeutic Agents: Changes in Colorectal Tumor Immune Cells After Targeting Serotonin

Study ID: NCT06225011

Conditions

Colorectal Adenocarcinoma

Interventions

Fluoxetine

Study Description

Brief Summary: This phase I trial tests whether fluoxetine (prozac) works to modify the tumor immune cells before surgery in patients with colorectal cancer. Fluoxetine is a commonly used selective serotonin reuptake inhibitor (SSRI) prescribed for major depressive disorder and generalized anxiety. Giving fluoxetine may modify the immune cell composition in the tumor and its microenvironment and may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread in patients with colorectal cancer.

Detailed Description: PRIMARY OBJECTIVE: I. To evaluate alterations in tumor immune cell composition and activity under SSRI treatment. OUTLINE: Patients receive fluoxetine orally (PO) once daily (QD) for 10 days prior to surgery.